Verghese Mathew MD FACC, FSCAI
Interventional Cardiology
Director Interventional Cardiology Swedish Hospital Endeavor Health Chicago, Illinois
5140 N. California Ave.Suite 700-GMPChicago, IL 60625
Fax+1 773-989-3971
Overview of Dr. Mathew
Dr. Mathew is Director, Interventional Cardiology at Swedish Hospital NorthShore University HealthSystem. He is also Director of WNICER, a global think tank and clinical trials collaborative which includes over 400 investigators around the world that have worked together on various trials, funded through federal and other sources. Until December, 2019 he was the Director, Division of Cardiology at Loyola University Medical Center, and held the rank of Professor of Medicine at Loyola University Chicago Stritch School of Medicine, and the William B. Knapp, MD Chair in Cardiology.
Dr. Mathew has been a high volume academic interventional cardiologist for more than 2 decades. He was a consultant cardiologist at Mayo Clinic from 1997-2016, holding a number of leadership positions in the cardiac and vascular arenas, with joint appointments in the departments of medicine, cardiology, and radiology; he was recruited to Loyola University Medical Center in 2016 to lead the division of cardiology.
Dr. Mathew has done extensive work in the field of interventional cardiology including complex CAD, peripheral arterial interventions, and TAVR- with both basic and translational research programs. He has been an investigator in many trials that have evaluated and led to the approval of currently utilized technologies, such as coronary stents/drug eluting stents and transcatheter aortic valve replacement (TAVR); as well as phase II-IV pharmacologic studies focused on antiplatelet and anticoagulant drugs in the context of coronary interventions. He has published extensively in the field of interventional cardiology. Dr. Mathew has a keen interest in integrated models of care, focusing on the appropriate application of advanced cardiovascular therapies to complex patient subsets. He continues to be an invited speaker at many national and international cardiovascular scientific conferences.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Interventional Cardiology, 1996 - 1997- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Cardiovascular Disease, 1993 - 1996
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1990 - 1993
Loyola University Chicago Stritch School of MedicineClass of 1990
Northwestern UniversityBA, Chemistry, 1983 - 1986
Certifications & Licensure
AZ State Medical License 2024 - 2026
FL State Medical License 1992 - 2026
IL State Medical License 2016 - 2026
WI State Medical License 2007 - 2025
MN State Medical License 1991 - 2017
American Board of Internal Medicine Cardiovascular Disease- American Board of Internal Medicine Interventional Cardiology
Awards, Honors, & Recognition
- Fellow Society for Cardiovascular Angiography and Interventions
- Fellow (FACC) American College of Cardiology
Clinical Trials
- PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk Start of enrollment: 2011 Mar 01
- Tailored Antiplatelet Therapy Following PCI Start of enrollment: 2013 May 01
- Cardiac Vascular Reconstruction DynaCT for TAVI Procedures Start of enrollment: 2014 Feb 01
Publications & Presentations
PubMed
- Coronary intravascular lithotripsy for acute stent underexpansion: a case series.Pooja Mishra, Jonathan Rosenberg, Verghese Mathew, Justin Levisay, Mark J Ricciardi
The Journal of Invasive Cardiology. 2025-09-30 - 1 citationsCost analysis of CYP2C19 genetic testing in percutaneous coronary intervention patients.Samuel Huxley, James Moriarty, Mark A Hlatky, Ryan Lennon, Kent Bailey
The Pharmacogenomics Journal. 2024-10-08 - Diastolic dysfunction and clinical outcomes after transcatheter or surgical aortic valve replacement in patients with atypical aortic valve stenosis.Rashad J Belin, Travis B Desa, Igor Wroblewski, Cara Joyce, Anthony Perez-Tamayo
Journal of Cardiovascular Medicine. 2024-04-01
Journal Articles
- Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary InterventionNaveen L Pereira, Verghese Mathew, Charles Cagin, Amir Lerman, Charanjit Rihal, JAMA
Authored Content
- Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary InterventionAugust 2020
- Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary InterventionAugust 2020
- Targeting Inflammation in the Prevention and Treatment of Type 2 Diabetes Insights from CANTOSMay 2018
Press Mentions
Grateful Heart Patient Gives $1.5 Million Gift to Loyola Medicine Cardiology DivisionJune 3rd, 2019- Mono-Antiplatelet Therapy After Aortic Heart Valve Replacements May Work as Well as Two DrugsAugust 14th, 2018
Cardiovascular Update C L I N I C a L Ca R D I O L O G Y a N D C a R D I O Va S C U L a R S U R G E R Y N E W SJuly 6th, 2017
Professional Memberships
- Fellow
- Fellow
Insurance Accepted
- Aetna Choice POS II
Anthem Blue Access PPO
Anthem Blue Preferred HMO
Anthem Blue Preferred Plus POS
BCBS Alabama PPO
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Minnesota Blue Cross Accord
CIGNA Open AccessCIGNA PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
